, Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus Optimizing outcome in SLE: treating-to-target and definition of treatment goals, Lupus. Autoimmun Rev, vol.1013, issue.2 27, pp.93-6770, 2001.
, Unmet medical needs in systemic lupus erythematosus, Arthritis Research & Therapy, vol.14, issue.Suppl 4, 2012.
DOI : 10.1136/ard.2010.142208
URL : https://arthritis-research.biomedcentral.com/track/pdf/10.1186/ar3919?site=arthritis-research.biomedcentral.com
, Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade, Annals of the rheumatic diseases, vol.69, issue.9, pp.1603-1614, 2010.
, Accrual of organ damage over time in patients with systemic lupus erythematosus, J Rheumatol, vol.30, issue.9, pp.1955-1964, 2003.
, Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus, Lupus, vol.30, issue.8, pp.949-56, 2010.
DOI : 10.1191/096120301670679959
, Genetics and novel aspects of therapies in systemic lupus erythematosus, Autoimmunity Reviews, vol.14, issue.11, pp.1005-1023, 2015.
DOI : 10.1016/j.autrev.2015.07.003
, Comparison of high versus low???medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis, Autoimmunity Reviews, vol.14, issue.10, pp.875-884, 2015.
DOI : 10.1016/j.autrev.2015.05.011
, Prednisone in lupus nephritis: How much is enough?, Autoimmunity Reviews, vol.13, issue.2, pp.206-220, 2014.
DOI : 10.1016/j.autrev.2013.10.013
, Pitfalls in lupus Treat-to-target in systemic lupus erythematosus: recommendations from an international task force, Autoimmun Rev. Annals of the rheumatic diseases, vol.1573, issue.116, pp.1089-93958, 2014.
, Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus, J Autoimmun. Arthritis Care Res, pp.2016-2030
, Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report EULAR recommendations for the management of systemic lupus erythematosus Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs, ) recommendations for the management of adult and paediatric lupus nephritis. Annals of the rheumatic diseases, pp.386-401195, 2008.
, American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis, Arthritis Care & Research, vol.63, issue.6, pp.797-808, 2012.
DOI : 10.1002/art.30293
URL : http://onlinelibrary.wiley.com/doi/10.1002/acr.21664/pdf
, Treatment Algorithms in Systemic Lupus Erythematosus Arthritis care & researchPrevention of infections in adults and adolescents with systemic lupus erythematosus: Guidelines for the clinical practice based on the literature and expert opinion]. La Revue de medecine interne / fondee par la Societe nationale francaise de medecine interne, pp.1237-45307, 2015.
, EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome, Ann Rheum Dis
, 23. HAS. Elaboration de recommandations de bonne pratique Méthode Recommandations par consensus formalisé. Guide méthodologique. 2010. 24 Assessment of disease activity in Systemic Lupus Erythematosus: Lights and shadows, Autoimmun Rev, vol.7514, issue.25, pp.795-810601, 2015.
, The role of B cells and autoantibodies in neuropsychiatric lupus, Autoimmunity Reviews, vol.15, issue.9, pp.890-895, 2016.
DOI : 10.1016/j.autrev.2016.07.009
URL : http://europepmc.org/articles/pmc4982790?pdf=render
, Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study, Arthritis Rheum. Arthritis Rheum. Autoimmun Rev, vol.626411, issue.295, pp.222-331215, 2010.
, Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry, Clin Exp Rheumatol, vol.33, issue.4, pp.449-56, 2015.
, A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-Clinical response compared to literature and immunological re-assessment Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry, Autoimmun Rev. Arthritis Rheum, vol.1462, issue.128, pp.2458-66, 2010.
, Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) -results from a nationwide cohort in Germany (GRAID) Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review, Lupus. Autoimmun Rev, vol.22, issue.11, p.35, 2013.
, Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study Group AT. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study, Arthritis Rheumatol. Arthritis Rheumatol, vol.6666, issue.3611, pp.379-893096, 2014.
DOI : 10.1002/art.38260
URL : http://onlinelibrary.wiley.com/doi/10.1002/art.38260/pdf
, The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial, Arthritis & Rheumatism, vol.61, issue.10, pp.3077-87, 2010.
DOI : 10.7326/0003-4819-144-12-200606200-00003
, Adverse events and efficacy of TNF-?? blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients, Rheumatology, vol.48, issue.20, pp.1451-1455, 2009.
DOI : 10.1001/archinte.165.20.2337
, Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients Hydroxychloroquine: a multifaceted treatment in lupus, al. Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: current views upon safety and immunogenicity, pp.542-52416, 2009.